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Abstract
Background: Changes in pulmonary hemodynamics and 
cardiac function in patients with chronic obstructive pulmo-
nary disease (COPD) traveling to altitude have not been as-
sessed despite an increasing prevalence of the disease. Ob-
jectives: We hypothesized that pulmonary artery pressure 
(PAP) significantly increases and cardiac function deterio-
rates during exposure to hypobaric hypoxia as encountered 
by traveling to moderate altitude or air flight. Methods: A 
total of 37 patients (17 female; median age [quartiles] 66 
years [60; 69] with COPD GOLD grade 2–3 [FEV1 57% pre-
dicted (49; 71)]) living < 800 m underwent echocardiography 
in Zurich (490 m) and after 1 night at Davos Jakobshorn 
(2,590 m) in a randomized order of allocation. Results: The 
transtricuspid pressure gradient increased from 23 mm Hg 
(18; 29) to 32 mm Hg (25; 41) (p < 0.0001; Δmedian [95% CI] 
7.5 [2.0; 13.0]), the right ventricular fractional area change 
decreased from 45% (39; 49) to 38% (33; 43) (p = 0.002), while 
the heart rate and systolic blood pressure increased from 70 
bpm (64; 78) to 82 bpm (70; 86) (p < 0.0001) and from 133 
mm Hg (123; 141) to 136 mm Hg (126; 148) (p = 0.002), re-
spectively, and left ventricular diastolic dysfunction was 
more prevalent (24–54%, p = 0.02). Conclusions: This is a first 
study assessing changes in pulmonary hemodynamics and 
cardiac function in patients with COPD during a short alti-
tude sojourn. Despite the increase in PAP and indications of 
change in cardiac function, the exposure was well tolerated. 
None of the patients had to descend to lower altitude for 
symptomatic altitude-related disease.
© 2018 S. Karger AG, Basel
Introduction
Despite an increasing prevalence of chronic obstruc-
tive pulmonary disease (COPD) in the general population 
and an increasing number of people traveling to high al-
titude due to professional and recreational activities, only 
few studies on COPD patients exposed to hypobaric hy-
poxia at altitude report about possible implications on 
ClinicalTrials.gov registration No. NCT0187513.
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health and preventive strategies [1–4]. The reported evi-
dence for an altitude-associated increase in mortality rate 
with COPD underscores the need for research in this field 
[5, 6]. This is especially true for countries in which part of 
the population lives at higher altitude.
COPD is the most common chronic respiratory dis-
ease worldwide and is characterized by chronic airflow 
obstruction with airway inflammation, remodeling, and 
parenchymal destruction of the lung (emphysema) in 
some patients. Cardinal symptoms of COPD are chronic 
productive cough and dyspnea on exertion with limited 
exercise performance related to dynamic hyperinflation, 
exercise desaturation, and an increase in pulmonary ar-
tery pressure (PAP) [7]. Pulmonary hypertension (PH) is 
a complication in COPD with increasing prevalence with 
the severity of parenchymal lung destruction due to loss 
of the pulmonary capillary bed, increased hypoxic pul-
monary vasoconstriction [8, 9], and left ventricular (LV) 
diastolic dysfunction [10]. Exercise-induced PH usually 
precedes resting PH; a sustained elevation of the mean 
PAP may ultimately lead to right ventricular (RV) failure 
and reduced survival rates [11, 12]. The structural and 
functional alterations of pulmonary vessels in patients 
with COPD increase the risk of developing symptomatic 
PH due to excessive hypoxic pulmonary vasoconstriction 
when traveling to altitude.
To date, the changes in cardiac function in lowlanders 
with COPD traveling to altitude are still incompletely un-
derstood. Therefore, the objective of our study was to per-
form a detailed echocardiographic and clinical investiga-
tion to quantify right and left heart function and hemody-
namics in lowlanders with COPD traveling to high altitude.
We hypothesized that PAP would significantly in-
crease and cardiac function deteriorate during exposure 
to even mild hypobaric hypoxia, similar to what is en-
countered by many tourists traveling to moderate altitude 
or by commercial air flight passengers exposed to an alti-
tude equivalent up to 8,000 ft (2,437 m).
Methods
Study Design and Subjects
The current data were collected from participants in a random-
ized crossover trial evaluating the exercise performance of COPD 
patients traveling from 490 to 2,590 m (ClinicalTrail.gov Identifi-
er: NCT01875133). In that study [13], clinical characteristics, pul-
monary function, and exercise tests were analyzed. The echocar-
diographic data reported here have not been published yet.
Men and women with moderate-to-severe COPD (GOLD 
grade 2 or 3) in stable condition living < 800 m and aged 18–75 
years were included in this study. Patients were excluded if the fol-
lowing criteria were met: hypoxemia at 490 m (PaO2 < 7.3 kPa); 
unstable condition; COPD exacerbation; uncontrolled cardiovas-
cular disease; use of drugs that affect respiratory center drive; 
known obstructive sleep apnea syndrome; any other pulmonary 
disease; internal, neurologic, or psychiatric disease that interferes 
with protocol compliance, including current heavy smoking (> 20 
cigarettes per day); previous intolerance to high altitude (< 2,600 
m); or pregnancy.
Interventions
The patients underwent clinical and echocardiographic assess-
ments at the University Hospital Zurich (490 m, low altitude; base-
line) and at the Hotel Davos Jakobshorn, Switzerland (2,590 m) in 
the afternoon after spending 1 night at altitude. Transfers between 
locations were made by train and cable car within 2–5 h. The alti-
tude exposure sequence was randomized according to a crossover 
design and a washout phase between examinations of > 2 weeks at 
490 m.
Assessments
Patients’ medical history was obtained, a clinical examination 
was performed, and the patients’ vital parameters were measured 
at each altitude. Lung function testing including diffusion capacity 
was conducted (BodystikTM and DiffustikTM; Geratherm Respira-
tory GmbH, Bad Kissingen, Germany). Six-minute walking dis-
tance was measured according to the guidelines of the American 
Thoracic Society [14].
Echocardiography
Doppler echocardiographic recordings were obtained with a 
real-time, phased array sector scanner (CX50 echocardiography 
unit with S5-1 transducer; Philips, Zofingen, Switzerland) accord-
ing to guidelines of the European Association of Echocardiogra-
phy [15–17]. The transtricuspid pressure gradient (TPG) was esti-
mated from the tricuspid regurgitation peak systolic flow velocity 
obtained with CW Doppler using the modified Bernoulli equation: 
ΔP = 4 × Vmax2. Right atrial pressure (RAP) was estimated by the 
respiratory variability in the diameter of the inferior vena cava. The 
systolic PAP (sPAP) was calculated as the summation of TPG and 
RAP [17]. Areas of the right atrium and RV were manually traced, 
and the RV fractional area change (FAC) was calculated. Tricuspid 
annular plane systolic excursion (TAPSE) was measured by M-
mode. The tissue Doppler systolic peak velocity of the RV free wall 
was assessed. The mean PAP was estimated from the acceleration 
time (AT) measured with PW Doppler in the RV outflow tract, as 
described by Kitabatake et al. [18]. To account for the influence of 
heart rate on AT, it was divided by heart rate.
The pulmonary artery wedge pressure (PAWP) was calculated 
using the Nagueh formula: PAWP = 1.24 × (E/e′) + 1.9 [19]. Dia-
stolic function was graded according to the 2009 EAE/ASE Recom-
mendations using septal e′, lateral e′, left atrial (LA) volume index, 
and E/A ratio. We considered septal e′ ≥8, lateral e′ ≥10, and LA 
volume index < 34 mL/m2 to signify normal diastolic function; if 
those thresholds were not met, diastolic dysfunction was consid-
ered and further assessed by E/A ratio and average E/e′ [20].
The imaging sequences were stored and double-checked by 
an independent echocardiographer (M.L.) blinded to the location. 
In case of relevant discrepancies in measurements, images were 
discussed among the echocardiographers – still blinded to loca- 
tion – and chosen upon agreement.
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Data Analysis and Statistics
Data analysis and statistics were performed with SPSS version 
22; for regression analysis, STATA version 15 was used. The anal-
ysis was performed according to the per protocol principle on par-
ticipants with data from both study locations. The data are sum-
marized as median (lower and upper quartile) or n (%). Effects of 
altitude were evaluated by Wilcoxon matched-pair tests or χ2 test 
and by computing mean differences with 95% CI.
Linear regression analysis was used to assess the potential ef-
fects of various baseline characteristics on the TPG at altitude. A 
probability of p < 0.05 was considered statistically significant.
Results
Of 191 screened patients, 151 could not be included for 
various reasons; 40 fulfilled the inclusion criteria and 
were randomized, but 3 patients withdrew their consent 
during the study (Fig.  1). Data about 37 patients were 
available for the per protocol analysis. Their characteris-
tics are presented in Table 1. Their median age (quartiles) 
was 66 years (60; 69), 54% of the participants were male, 
the body mass index was 28.1 (22.1; 30.2), the median 
FEV1 was 57% predicted (49; 71), and FEV1/FVC was 
51% (42; 60). Comorbidities included arterial hyperten-
sion in 62% and stable cardiovascular diseases in 23% of 
the patients.
The evaluation at 2,590 m, after the patients had spent 
1 night at 2,590 m, revealed a significant decrease in PaO2 
from 9.0 kPa (8.4; 9.4) to 6.6 kPa (6.3; 7.2) along with a 
reduced SaO2 from 94% (93; 95) to 87% (84; 91) (both 
p < 0.001). This was generally well tolerated. None of the 
patients had to descend to lower altitude for symptom-
atic altitude-related disease; however, 5 patients required 
supplemental oxygen therapy during the night because of 
severe nocturnal hypoxemia (defined as SpO2 < 80% for 
≥30 min).
Assessments at 2,590 m
n = 19
(2 patients received oxygen
therapy during the night)
151 were not eligible:
 139 refused to participate
 5 unstable cardiovascular disease
 3 ODI >15/h
 2 medication interfering with sleep
 1 hypoxemia at low altitude (PaO2 <7.3 kPa)
 1 psychiatric disorder
191 patients were assessed for eligibility
40 underwent randomization
Per protocol analysis
n = 37
Assessments at 490 m
n = 21
Assessments at 2,590 m
n = 19
(3 patients received oxygen
therapy during the night)
Assessments at 490 m
n = 18
2-week washout period
at <800 m
2 withdrew
consent
2-week washout period
at <800 m
1 withdrew
consent
Fig. 1. Flowchart of the study. ODI, oxygen desaturation index.
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Right Heart Function and Morphology
The pulmonary hemodynamics and RV function are 
shown in Table 2. The tricuspid regurgitation peak sys-
tolic velocity (TRV) and consecutive TPG showed a sig-
nificant increase (TRV from 2.4 m/s [2.1; 2.7] to 2.8 m/s 
[2.5; 3.2], p < 0.0001; TPG from 23 mm Hg [18; 29] to 32 
mm Hg [25; 41], p < 0.0001) (Fig. 2, 3). At low altitude, 6 
patients had a TRV > 2.8 m/s, and at high altitude this was 
the case for 18 patients. The RV outflow tract AT in-
creased with altitude, even when indexed for heart rate 
(Table 2); correspondingly, the mean PAP increased from 
19 mm Hg (16; 20) to 28 mm Hg (22; 37) (p = 0.0001). 
The RV end-systolic area increased, while the RV end-
diastolic area remained unchanged, resulting in a reduced 
RV FAC and an increase in RAP. The RV wall thickness, 
RV/LV ratio, eccentricity indices, septal motion, TAPSE, 
and tissue Doppler RV systolic excursion velocity s′ re-
mained unchanged.
Left Heart Function and Morphology
All participants had normal LV systolic function at 490 
m. With ascent from 490 to 2,590 m, there was a significant 
increase in heart rate and a slight increase in systemic sys-
tolic blood pressure, a small increase in aortic root diame-
ter, and a minor reduction of the LV ejection fraction 
(LVEF) (Table 3). The mitral E/A ratio, septal mitral annu-
lus e′ wave, and average mitral annulus e′, as well as the 
septal E/e′ ratio and the lateral and septal e′/a′ ratio, re-
mained unchanged. The percentage of subjects with dia-
stolic dysfunction, which was assessed individually accord-
ing to the 2009 EAE/ASE guidelines [20], doubled with as-
cent to 2,590 m (from 24 to 54%, p = 0.012). No significant 
change in LA dimensions and in PAWP occurred (Table 3).
Correlation and Regression Analysis
Multivariate linear regression analysis revealed a weak 
correlation between baseline TPG and TPG at altitude 
(Table 4). No other relevant associations between poten-
tial clinical characteristics and right or left heart param-
eters were found in univariate analysis.
Discussion
To our knowledge, the current study is the first com-
prehensive clinical and echocardiographic evaluation of 
lowlanders with moderate-to-severe COPD at 2,590 m. 
The main findings on the day after arrival at the higher 
altitude consisted of a moderate increase in heart rate and 
PAP associated with a reduced RV FAC and an increase 
in RAP. In addition, there was an increase in systemic 
systolic blood pressure, a minor reduction in LVEF, and 
an increase in the prevalence of diastolic dysfunction by 
more than half from 24 to 54% of the participants. These 
novel findings suggest that the hypoxemia experienced by 
COPD patients going to an altitude as encountered in 
many tourist destinations or during commercial air trav-
el is causing considerable impairment of the pulmonary 
and systemic circulation that may possibly contribute to 
exercise limitation or even predispose to cardiac failure.
Table 1. Patient characteristics
Zurich (490 m)
Subjects, n 37; 20 men (54%)
Age, years 66 (60; 69)
Height, cm 170 (165; 177)
Weight, kg 78 (66; 88)
Body surface area, m2 1.9 (1.7; 2.0)
Body mass index 28.1 (22.1; 30.2)
PaO2, kPa 9.0 (8.3; 9.4)
SaO2, % 94 (93; 95)
GOLD grade 2/3 21/16 (57/43)
Current/ex-/no smoker 8/28/1 (23/76/2)
Pack-years 45 (20; 68)
Lung function testing
FEV1, % predicted (after bronchodilation) 57 (49; 71)
FEV1/FVC ratio 51 (42; 61)
DLCO (Hb), % predicted 58 (49; 68)
Arterial hypertension 23 (62)
Cardiovascular disease (CAD, PAOD, CVI) 8 (23)
Six-min walking distance, m 542 (471; 585)
SpO2 end 6-min walking distance, % 89 (82; 92)
Inhalation of glucocorticoids 23 (62)
Inhalation of β-mimetics 31 (84)
Inhalation of anticholinergics 30 (81)
Roflumilast 3 (8)
Theophylline 2 (5)
Diuretics 10 (27)
ACE inhibitor or AT2 antagonist 20 (54)
β-Blocker 8 (22)
Calcium channel blocker 6 (16)
Lipid-lowering therapy 7 (19)
Antidiabetics 2 (5)
Antidepressants 7 (19)
Antiplatelet aggregation therapy 7 (19)
Data are displayed as median (quartiles) or n (%). PaO2, oxygen partial 
pressure in arterial blood; SaO2, oxygen saturation in arterial blood; SpO2, 
oxygen saturation pulse oximetry; FVC, forced vital capacity; FEV1, forced 
expiratory volume in 1 s; DLCO (Hb), diffusing capacity for carbon monoxide 
(adjusted for hemoglobin); CAD, coronary artery disease; PAOD, peripheral 
arterial occlusive disease; CVI, cerebrovascular insult; ACE, angiotensin-
converting enzyme.
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In the literature, many previous studies observing ef-
fects of acute exposure to hypobaric or normobaric hy-
poxia have described increases in PAP in healthy subjects: 
Kriemler et al. [21] performed an echocardiographic field 
study on 20 healthy individuals (mean age 44 years) and 
revealed an increase in mean sPAP from 24 mm Hg at 450 
m to 32 mm Hg on the first day at 3,450 m. Similar results 
from younger study collectives have been reported by 
several other authors describing sPAP values ranging 
from 30 ± 6 mm Hg at 3,730 m to 41 ± 3 mm Hg at 5,000 
m [22–28]. Thus, with an estimated sPAP of 28 mm Hg 
(24; 35) at 490 m, the current COPD patients already 
started with higher pressures at low altitude when com-
pared to healthy subjects, and furthermore showed a 
greater increase when ascending to 2,590 m; such values 
were reported for healthy subjects only at very high alti-
tudes (> 4,500 m) [22–27].
Even though our COPD patients had values corre-
sponding to those in healthy subjects at very high altitude, 
they tolerated the exposure to this altitude well, which 
might be explained by an as yet unknown RV adaptation 
to hypoxia caused by their underlying pulmonary disease 
[29]. The higher PAP in COPD patients is most likely due 
to both restriction of the pulmonary vascular bed due to 
parenchymal destruction of the lung and a greater degree 
of hypoxemia with excessive hypoxic pulmonary vaso-
constriction. We did not find any significant increase in 
breath rate or dynamic hyperinflation with altitude in the 
present COPD cohort [30], and changes in functional re-
sidual capacity and the TPG were not correlated. Thus, 
we do not think that any changes in respiratory mechan-
ics contributed to the increase in PAP in these patients.
In the present study, we did not assess stroke volume 
and cardiac output, and thus we cannot address potential 
changes in pulmonary vascular resistance with altitude, 
which should be included in future research. The higher 
age of the COPD patients and their impaired LV diastol-
ic function may additionally have contributed. However, 
only a minority (16%) of the COPD patients in our cohort 
had a TPG velocity > 2.8 m/s, as suggestive of potential PH 
group 3 in Zürich (460 m), but none had signs of right 
heart failure.
In the current COPD collective, we found a slightly 
increased RV end-systolic area and a slightly lower RV 
FAC at altitude, suggesting mild impairment of RV func-
tion probably due to an elevated afterload caused by the 
increased PAP. These results are in accordance with data 
published by Güvenç et al. [31] describing larger end- 
diastolic and end-systolic RV diameters and end-systolic 
areas as well as reduced FAC in patients with COPD liv-
Table 2. Right heart function and morphology (n = 37)
Variables Zurich 
(490 m)
Jakobshorn 
(2,590 m)
Median change 
(95% CI)
p
Tricuspid valve regurgitation peak systolic velocitya, m/s 2.4 (2.2; 2.7) 2.8 (2.5; 3.2) 0.5 (0.3; 0.6) <0.0001*
Transtricuspid pressure gradient, mm Hg 23 (19; 29) 32 (25; 41) 7.5 (2.0; 13.0) 0.0001*
Systolic pulmonary artery pressure, mm Hg 28 (24; 35) 39 (34; 49) 8.0 (6.0; 16.6) <0.0001*
RV outflow tract acceleration time, s 121 (117; 133) 96 (81; 112) –20 (–40.5; –9) 0.0001*
RV outflow tract acceleration time/heart rate ratio 1.7 (1.5; 2.0) 1.2 (0.9; 1.5) –0.4 (–0.7; –0.2) <0.0001*
Mean pulmonary artery pressure, mm Hg 19 (16; 20) 28 (22; 37) 7.1 (3.1; 14.1) 0.0001*
RV end-diastolic area, cm2 15 (14; 18) 16 (14; 19) 0.4 (–0.9; 1.9) 0.22
RV end-systolic area, cm2 8 (8; 11) 11 (8; 12) 1.44 (0.4; 2.4) 0.02*
RV fractional area change, % 45 (39; 49) 38 (33; 43) –7.0 (–10.6; –2.9) 0.002*
RV anterior wall thickness, cm 0.5 (0.4; 0.5) 0.5 (0.4; 0.6) 0.0 (–0.0; 0.1) 0.29
RV/LV ratio 0.4 (0.3; 0.6) 0.4 (0.2; 0.5) –0.0 (–0.1; 0.0) 0.33
Eccentricity index – diastolic 1.0 (0.9; 1.1) 1.0 (0.9; 1.1) –0.0 (–0.1; 0.0 0.17
Eccentricity index – systolic 1.0 (0.9; 1.1) 1.0 (1.0; 1.1) –0.0 (–0.1; 0.2) 0.68
Patients with septal motion deviation 1 (3) 2 (5) 1.0
Tricuspid annular plane systolic excursion, cm 2.3 (2.2; 2.5) 2.3 (2.0; 2.5) 0.0 (–0.2; 0.2) 0.43
RV systolic excursion velocity s′, cm/s 13 (12; 15) 14 (12; 16) 0.6 (–0.7; 1.6) 0.33
Right atrial pressure, mm Hg 5 (5; 5) 5 (5; 10) 0.0 (0.0; 0.0) <0.001*
Right atrial area, cm2 13 (12; 17) 13 (12; 17) –0.6 (–2.4; 0.8) 0.39
Data are displayed as median (quartiles) or n (%). RV, right ventricular; LV, left ventricular. * p < 0.05. a Tricuspid valve regurgitation 
peak systolic velocity could be obtained from 32 of the 37 patients at 490 m and from 35 of the 37 patients at 2,590 m.
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ing at moderate altitude. As in our study collective, Gü-
venç et al. [31] could not detect any difference in TAPSE 
when comparing patients with COPD living at sea level 
with those living at moderate altitude, which might indi-
cate that impairments of RV function are only mild, 
mainly driven by an increased volume and an only minor 
reduction in contractility.
The expected increase in heart rate and systemic blood 
pressure, as known from sojourns to altitude in healthy 
subjects due to chemoreceptor activation [32], could like-
wise be observed in this COPD cohort. The systolic LVEF 
was slightly but significantly reduced at 2,590 m – albeit 
with a median decrease of only 5%, which should be in-
terpreted with caution, since it could be within the range 
of measurement variability [33]. In contrast, recent stud-
ies have reported an increase in EF with acute exposure 
to 3,700 m [34] (n = 139) and 3,750 m (n = 15) in healthy 
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Fig. 2. Transtricuspid pressure gradient (a), mean pulmonary artery wedge pressure (PAWP) (b), right ventricu-
lar (RV) fractional area change (c), and RV end-systolic area (d) at 490 and 2,590 m are shown. Boxplot horizon-
tal lines represent median values, box borders display quartiles, and upper and lower whiskers display the last 
value that is in between 1.5× the interquartile range.
Fig. 3. Individual changes in transtricuspid pressure gradient.
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subjects [28]. Thus, the measured reduction in EF in our 
COPD collective seems to be noteworthy. In addition, di-
astolic dysfunction seemed to increase with exposure to 
higher altitude.
On PW tissue Doppler imaging of the mitral annulus, 
especially the septal E/e′ ratio increased with altitude, 
which may suggest a slightly increased LV filling pres-
sure, even though the estimated PAWP and indexed LA 
volume were unchanged. In healthy individuals, previ-
ous studies have shown significant changes in E/A ratio 
during sojourns to high altitude [25, 28, 35, 36]. Gibbs 
[37] postulated that impaired diastolic LV filling at alti-
tude is a consequence of an RV pressure overload causing 
impaired RV function, a reduction of the stroke volume, 
and thus venous return to the LA. However, Bernheim et 
al. [38] could not detect any correlation between LV dia-
stolic dysfunction and acute changes in PAP due to exer-
cise and exposure to high altitude in healthy subjects. It 
remains unclear if increases in PAP may be attributed to 
diastolic dysfunction or vice versa. The previously men-
tioned study by Güvenç et al. [31] found no significant 
difference in mitral E or A wave between patients with 
COPD living at sea level and those living at moderate al-
titude (1,768 m). A partial influence of impaired LV dia-
stolic function on increases in PAP cannot be complete-
ly dismissed, even though an association was not found 
in our regression analysis. It remains unclear whether LV 
systolic and diastolic dysfunction at altitude can be at-
tributed to underlying cardiovascular diseases or wheth-
er it is the cause or the consequence of the increased PAP. 
In this COPD collective with prevalent comorbidities, it 
is conceivable that coronary heart disease and systemic 
arterial hypertension contributed to LV dysfunction 
during the exposure to altitude in some of the patients, 
but further studies are needed to clarify these assump-
tions.
Table 3. Left heart function and morphology (n = 37)
Variables Zurich 
(490 m)
Jakobshorn 
(2,590 m)
Median change 
(95% CI)
p
Heart rate, bmp 70 (64; 78) 82 (70; 86) 7 (3; 12) <0.0001*
Blood pressure – systolic, mm Hg 133 (123; 141) 136 (126; 148) 4.5 (–1.5; 11.5) 0.02*
Blood pressure – diastolic, mm Hg 81 (75; 87) 80 (72; 94) 0.0 (–3.5; 2.0) 0.96
Blood pressure – mean, mm Hg 99 (91; 104) 97 (92; 111) 1.0 (–3.0; 3.5) 0.44
Aortic root diameter, cm 3.2 (2.6; 3.5) 3.5 (3.1; 3.8) 0.2 (0.1; 0.4) 0.0002*
LV ejection fraction (Simpson), % 67 (63; 70) 64 (59; 67) –4.9 (–6.9; –1.9) 0.04*
Septal wall thickness, cm 0.9 (0.8; 1.1) 1.0 (0.9; 1.1) 0.1 (0.0; 0.2) 0.006*
LV end-diastolic dimension, cm 4.7 (4.1; 4.9) 4.5 (4.1; 5.0) 0.0 (–0.3; 0.2) 0.63
LV end-systolic dimension, cm 2.9 (2.6; 3.2) 2.9 (2.6; 3.3) 0.1 (–0.1; 0.2) 0.57
LV end-diastolic posterior wall, cm 0.7 (0.6; 0.7) 0.7 (0.6; 0.9) 0.03 (–0.0; 0.1) 0.04*
Mitral annulus motion, cm 1.5 (1.4; 1.7) 1.7 (1.5; 1.8) 0.1 (–0.0; 0.2) 0.15
Mitral E wave, m/s 72 (63; 83) 73 (59; 88) –1.3 (–10.5; 3.4) 0.44
Mitral A wave, m/s 69 (57; 81) 64 (55; 82) –1.7 (–6.7; 8.5) 0.78
Mitral E/A ratio 1.0 (0.8; 1.1) 0.8 (0.8; 1.1) –0.0 (–0.1; 0.8) 0.38
Lateral mitral annulus a′ wave. cm/s 11 (10; 14) 13 (11; 15) 0.4 (–0.2; 2.1) 0.06
Septal mitral annulus a′ wave, cm/s 11 (10; 13) 11 (9; 13) 0.1 (–1.3; 1.0) 0.68
Lateral mitral annulus e′ wave, cm/s 10 (9; 13) 10 (8; 12) –0.8 (–1.5; 0.1) 0.11
Septal mitral annulus e′ wave, cm/s 9 (8; 10) 8 (6; 9) –1.8 (–2.2; –1.0) 0.0004*
Average mitral annulus e′ wave, cm/s 10 (9; 11) 9 (7; 11) –1.4 (–2.0; –0.2) 0.003*
Lateral E/e′ ratio 6.5 (5.0; 7.6) 6.5 (4.6; 9.5) –0.1 (–1.0; 1.8) 0.38
Septal E/e′ ratio 7.1 (6.3; 8.1) 8.0 (6.7; 12.2) 1.4 (–0.0; 2.9) 0.01*
Lateral e′/a′ ratio 0.9 (0.7; 1.2) 0.7 (0.6; 0.9) –0.1 (–0.2; –0.1) 0.002*
Septal e′/a′ ratio 0.8 (0.7; 1.0) 0.7 (0.6; 0.9) –0.1 (–0.3; 0.0) 0.01*
Patients with diastolic dysfunction 9 (24) 20 (54) 0.02*
Left atrial diameter, cm 3.6 (3.0; 4.0) 3.4 (3.0; 3.9) 0.0 (–0.3; 0.4) 0.44
Left atrial volume index, mL/m2 21 (17; 27) 20 (16; 26) –0.7 (–2.8; 3.0) 0.92
Pulmonary artery wedge pressure, mm Hg 10 (9; 12) 11 (9; 15) 0.3 (–0.3; 2.7) 0.11
Data are displayed as median (quartiles) or n (%). LV, left ventricular. * p < 0.05.
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Whether the increase in PAP and the deterioration in 
RV function in lowlanders with COPD is sustained dur-
ing prolonged exposure to altitude and associated with 
clinically relevant altitude-related adverse health effects, 
or whether acclimatization will improve the acute dete-
rioration, is not known. Güvenç et al. [31] have shown a 
significantly higher PAP in high-altitude residents with 
COPD, and additionally it has been shown that COPD is 
associated with higher mortality among inhabitants of 
higher altitudes compared to lowlanders; however, the 
underlying mechanism is not yet understood [5, 6]. It 
might be postulated that the impairment of pulmonary 
vascular and RV function is one possible explanation.
Limitations
The accuracy of echocardiography in assessing cardiac 
function depends on acoustic windows; thus, it can be dif-
ficult to acquire data of sufficient quality from patients 
with COPD and emphysema. In our cohort, the echo 
quality was sufficient to assess predefined parameters in 
the vast majority of patients, i.e., the TPG could be esti-
mated in 32 (low altitude) and 35 (high altitude) of the 37 
participants. Estimates of sPAP, although highly reliable 
[39], can be under- or overestimated when tricuspid re-
gurgitation is minimal, and thus right heart catheteriza-
tion would be the investigation of choice; however, this 
procedure was not feasible for this patient population due 
to its invasive nature and logistic constraints. The ran-
domized crossover design and blinded double check of 
stored echocardiographic images were used to limit mea-
surement and sequence biases to the greatest possible ex-
tent.
In all, 139 COPD patients from different pulmonology 
ambulatories throughout Switzerland contacted via tele-
phone refused to participate in this study, mainly due to 
logistical reasons (subjectively long travel distances and 
no time to spend 2 nights at altitude and 1 in Zurich). A 
possible bias can neither be excluded nor derived from 
those refusals. Furthermore, only patients with COPD 
GOLD grade 2 or 3 with preserved functional capacity 
and mild hypoxemia were accepted into the study; there-
fore, we are not able to comment on any pulmonary vas-
cular changes and the cardiac function of patients with 
very severe COPD and worse functional capacities, and at 
higher altitudes than 2,590 m.
Conclusion
This is the first study assessing pulmonary hemody-
namics along with RV and LV function in lowlanders 
with COPD GOLD grade 2 or 3 after 1 night at an altitude 
Table 4. Linear regression analysis of predictors of the TPG at 2,590 m
Dependent variable: 
TPG at 2,590 m (mm Hg)
Univariate Multivariate
coefficient 95% CI p coefficient 95% CI p
Age (years) –0.5 –1.3 to 0.4 0.324 0.05 –0.6 to 0.7 0.884
Gender –5.9 –14.8 to 2.9 0.179 –7.8 –15.9 to 0.2 0.056
BMI 0.5 –0.6 to 1.5 0.369
FEV1 (% predicted) –30.0 –69.4 to 9.4 0.130
SpO2 peak 6MWD (%) –0.8 –1.8 to 0.3 0.143
DLCO (Hb) (% predicted) –0.15 –0.5 to 0.2 0.360
TPG at 490 m (mm Hg) 0.7 –0.01 to 1.5 0.054 0.8 0.1 to 1.5 0.029
Ejection fraction (%) –0.04 –0.07 to 0.6 0.892
Diastolic dysfunction 0.1 –7.9 to 8.1 0.982
Blood pressure – systolic (mm Hg) –0.1 –0.3 to 0.1 0.138
Heart rate (bpm) 0.1 –0.2 to 0.5 0.411
aHTN/CVD 6.1 –1.9 to 14.1 0.129
SpO2 (%) 0.9 –1.8 to 3.5 0.508
PaO2 (kPa) –0.6 –2.7 to 1.6 0.602
For all independent variables, baseline measurements at 490 m were included into the analysis. R2 = 0.315 and p = 0.07 for multivariate 
regression. TPG, transtricuspid pressure gradient; BMI, body mass index; SpO2, oxygen saturation; 6MWD, 6-min walking distance; 
DLCO (Hb), diffusing capacity for carbon monoxide (adjusted for hemoglobin); aHTN, arterial hypertension; CVD, cardiovascular 
disease; PaO2, oxygen partial pressure in arterial blood.
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of 2,590 m. Hypobaric hypoxia was associated with an 
increase in PAP comparable to that reported for healthy 
subjects at much higher altitude, i.e., > 4,500 m. More-
over, the COPD patients, some of them with treated 
hypertension and/or stable cardiovascular disease, dis-
played an increase in systemic systolic blood pressure, a 
very slight reduction in LVEF, and potential signs of dia-
stolic dysfunction. Despite these cardiovascular impair-
ments, the patients tolerated the exposure to altitude well, 
and none of the participants had to descend to lower al-
titude due to symptomatic altitude-related disease.
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